Literature DB >> 20183441

Assessing cytotoxic treatment effects in preclinical tumor xenograft models.

Jianrong Wu1, Peter J Houghton.   

Abstract

In preclinical solid tumor xenograft experiments, tumor response to cytotoxic agents is often assessed by tumor cell kill. Log10 cell kill (LCK) is commonly used to quantify the tumor cell kill in such experiments. For comparisons of antitumor activity between tumor lines, the LCK values are converted to an arbitrary rating; for example, the treatment effect is considered significant if the LCK > 0.7 (Corbett et al., 2003). The drawback of using such a predefined cutoff point is that it does not account for the true variation of the experiments. In this article, a nonparametric bootstrap percentile interval of the LCK is proposed. The cytotoxic treatment effect can be assessed by the confidence limits of the LCK. Monte Carlo simulations are conducted to study the coverage probabilities of the proposed interval for small samples. Tumor xenograft data from a real experiment are analyzed to illustrate the proposed method.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20183441      PMCID: PMC2978919          DOI: 10.1080/10543400903105158

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  5 in total

1.  The pediatric preclinical testing program: description of models and early testing results.

Authors:  Peter J Houghton; Christopher L Morton; Chandra Tucker; Debbie Payne; Edward Favours; Claire Cole; Richard Gorlick; E Anders Kolb; Wendong Zhang; Richard Lock; Hernan Carol; Mimi Tajbakhsh; C Patrick Reynolds; John M Maris; Joshua Courtright; Stephen T Keir; Henry S Friedman; Charles Stopford; Joseph Zeidner; Jianrong Wu; Tiebin Liu; Catherine A Billups; Javed Khan; Sherry Ansher; Jian Zhang; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2007-12       Impact factor: 3.167

2.  Nonparametric estimation for the difference or ratio of median failure times.

Authors:  J Q Su; L J Wei
Journal:  Biometrics       Date:  1993-06       Impact factor: 2.571

3.  Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.

Authors:  Thomas H Corbett; Kathryn White; Lisa Polin; Juiwanna Kushner; Jennifer Paluch; Chuan Shih; Cora Sue Grossman
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

4.  Methods for analysis of censored tumor growth delay data.

Authors:  M Stuschke; V Budach; M Bamberg; W Budach
Journal:  Radiat Res       Date:  1990-05       Impact factor: 2.841

5.  Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

Authors:  E Anders Kolb; Richard Gorlick; Peter J Houghton; Christopher L Morton; Richard Lock; Hernan Carol; C Patrick Reynolds; John M Maris; Stephen T Keir; Catherine A Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2008-06       Impact factor: 3.167

  5 in total
  5 in total

1.  Assessment of antitumor activity for tumor xenograft studies using exponential growth models.

Authors:  Jianrong Wu
Journal:  J Biopharm Stat       Date:  2011-05       Impact factor: 1.051

2.  A simulation-based sample size calculation method for pre-clinical tumor xenograft experiments.

Authors:  Jianrong Wu; Shengping Yang
Journal:  J Biopharm Stat       Date:  2017-04-27       Impact factor: 1.051

3.  Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.

Authors:  Jianrong Wu
Journal:  Pharm Stat       Date:  2013-03-07       Impact factor: 1.894

4.  Confidence intervals for the difference of median failure times applied to censored tumor growth delay data.

Authors:  Jianrong Wu
Journal:  Stat Biopharm Res       Date:  2012-01-24       Impact factor: 1.452

5.  Inhibitor of MYC identified in a Kröhnke pyridine library.

Authors:  Jonathan R Hart; Amanda L Garner; Jing Yu; Yoshihiro Ito; Minghao Sun; Lynn Ueno; Jin-Kyu Rhee; Michael M Baksh; Eduard Stefan; Markus Hartl; Klaus Bister; Peter K Vogt; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.